Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey

被引:10
|
作者
Kaur, Sukhpal [1 ]
Singh, Ajay [2 ]
Saini, Sushma [1 ]
Rohilla, Latika [1 ]
Kaur, Jasvir [1 ]
Chandi, Anadeep [3 ]
Kaur, Gurpreet [1 ]
Singh, Manjeet [9 ]
Kumar, Pramod [1 ]
Soni, Shiv Lal [10 ]
Kajal, Kamal [2 ]
Naik, Naveen B. [2 ]
Malhotra, Pankaj [4 ]
Verma, Sanjay [5 ]
Gupta, Madhu [6 ]
Devnani, Mahesh [7 ]
Das, Karobi [1 ]
Pandav, S. S. [8 ]
Puri, G. D. [2 ]
机构
[1] Govt Multispecial Hosp, Natl Inst Nursing Educ, Dept Nursing, Chandigarh, India
[2] Govt Multispecial Hosp, Dept Anaesthesia & Intens Care, Chandigarh, India
[3] Govt Multispecial Hosp, Dept Obstet & Gynaecol, Chandigarh, India
[4] Govt Multispecial Hosp, Dept Internal Med, Chandigarh, India
[5] Govt Multispecial Hosp, Dept Paediat, Chandigarh, India
[6] Govt Multispecial Hosp, Dept Community Med, Chandigarh, India
[7] Govt Multispecial Hosp, Hosp Adm, Chandigarh, India
[8] Multispecial Hosp, Postgrad Inst Med Educ & Res, Ophthalmol, Chandigarh, India
[9] Govt Multispecial Hosp, Dept Med, Chandigarh, India
[10] Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Sect 12, Chandigarh 160012, India
关键词
Adverse events; ChAdOx1; nCoV-19; coronavirus disease 2019; healthcare professionals; side effects; vaccination;
D O I
10.4103/ijmr.ijmr_1221_21
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background & objectives: The safety of the ChAdOx1 nCoV-19 vaccine is a cause of concern for many who have been vaccinated. The people have multiple concerns and fear regarding the adverse events of the vaccine. Thus, this study was undertaken to establish the safety profile of ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) among the healthcare professionals. Methods: This was a descriptive cross-sectional survey. After taking clearance from the institutional ethics committee 1500 healthcare professionals, who had their vaccination in the past two weeks were selected. They were provided with an online survey proforma regarding adverse events following immunization (AEFIs) of COVID-19 vaccine developed using google forms with an informed consent form affixed to it. Results: A total of 1036 individuals participated in the study. The mean and median (inter quartile range) age of the participants was 37.7 +/- 11.25 and 35 (29-46) yr, respectively. Of these, 52.1 per cent were female, 29.3 per cent were doctors, 33.4 per cent were nurses and 9.5 per cent were paramedical staff. Forty six per cent participants experienced one or more minor AEFIs such as pain, tenderness, redness, etc. at the injection site. Fatigue (31.75%), generalized feeling of unwell (28.57%), muscle pain (23.16%) and fever (21.71%) were the most commonly reported systemic AEFIs followed by headache (20.07%), dizziness (10.03%) and joint pains (15.25%). Most of them experienced these AEFIs within 24 h of the first dose of administration. About 42 per cent of the participants took oral antipyretics/analgesics for managing the AEFIs. Interpretation & conclusions: ChAdOx1 nCoV-19 Corona Virus Vaccine was found to be associated with mild local and systemic AEFIs that were more common after the first dose as compared to the second dose. There adverse events could be dealt with oral over-the-counter medications, with no requirement of hospitalization.
引用
收藏
页码:123 / 128
页数:6
相关论文
共 50 条
  • [21] Incidence of early adverse events following covishield (ChAdOx1 nCoV-19) vaccination: A prospective study
    Velhal, Gajanan D.
    Kamath, Yash, V
    Agrawal, Ansh S.
    Vora, Devanshi S.
    Dwivedi, Vaibhav R.
    INDIAN JOURNAL OF COMMUNITY MEDICINE, 2022, 47 (04) : 613 - 617
  • [22] Comparing ChAdOx1 nCoV-19 Coronavirus Vaccine (Recombinant) (Covishield) and BBV152; Bharat Biotech COVID-19 Vaccine (Covaxin) for COVID-19: Reports of Adverse Events Following Vaccination among the Indian Population
    Kaur, Sukhpal
    Rohilla, Latika
    Kayina, Choro Athiphro
    Kaur, Jasvir
    Kaur, Gurpreet
    Walia, Anjani
    Kumar, Pramod
    Singh, Ajay
    Saini, Sushma
    Soni, Shiv Lal
    Malhotra, Pankaj
    INDIAN JOURNAL OF PUBLIC HEALTH, 2025, 69 (01) : 27 - 32
  • [23] Vaccination-associated immune thrombocytopenia possibly due to ChAdOx1 nCoV-19 (Covishield) coronavirus vaccine
    Sivaramakrishnan, Prakash
    Mishra, Mayank
    BMJ CASE REPORTS, 2022, 15 (03)
  • [24] A case of acute endothelial corneal transplant rejection following immunization with ChAdOx1 nCoV-19 coronavirus vaccine
    Nahata, Harshita
    Nagaraja, Harsha
    Shetty, Rohit
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2022, 70 (05) : 1817 - 1818
  • [25] Detection of Short-Term Side Effects of ChAdOx1 nCoV-19 Vaccine: A Cross-Sectional Study in a War-Torn Country
    Alshakka, Mohammed
    Hatem, Najmaddin A. H.
    Badullah, Wafa
    Alsakaf, Rabab
    Rageh, Ali
    Yousef, Seena Abdulla
    Ibrahim, Mohamed Izham Mohamed
    PRAGMATIC AND OBSERVATIONAL RESEARCH, 2022, 13 : 85 - 91
  • [26] Adverse events following introduction of the ChAdOx1 nCoV-19 vaccine in Somalia in 2021: findings from a fragile setting and implications for the future
    Hamayoun, Mohammad
    Abdulrazak, Ibrahim
    Farid, Muhammad
    Malik, Mamunur Rahman
    Farah, Mohammed
    IJID REGIONS, 2022, 4 : 47 - 52
  • [27] Recurrent Anterior Non-necrotizing Scleritis as an Adverse Event of ChAdOx1 nCoV-19 (Vaxzevria) Vaccine
    Hernanz, I.
    Arconada, C.
    Lopez Corral, A.
    Sanchez-Pernaute, O.
    Carreno, E.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2022, 30 (05) : 1247 - 1249
  • [28] Occurrence of COVID-19 in priority groups receiving ChAdOx1 nCoV-19 coronavirus vaccine (recombinant): A preliminary analysis from north India
    Kaur, Upinder
    Bala, Sapna
    Ojha, Bisweswar
    Jaiswal, Sumit
    Kansal, Sangeeta
    Chakrabarti, Sankha S.
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (01) : 407 - 412
  • [29] Surveillance on Adverse Events Following COVISHIELD (ChAdOx1 nCoV-19) vaccination in Goa, India: An Observational Study
    Jose, Dhanya
    Dhupdale, Nitin
    Cacodcar, Jagadish A.
    Kamat, Umesh
    CURRENT DRUG SAFETY, 2023, 18 (04) : 516 - 527
  • [30] Acute Cardiac Events After ChAdOx1 nCoV-19 Corona Virus Vaccine: Report of Three Cases
    Singh, Rohit
    Chakrabarti, Sankha Shubhra
    Gambhir, Indrajeet Singh
    Verma, Ashish
    Kumar, Ishan
    Ghosh, Soumik
    Tiwari, Ashutosh
    Chandan, Gourav
    Chakrabarti, Sasanka
    Kaur, Upinder
    AMERICAN JOURNAL OF THERAPEUTICS, 2022, 29 (05) : E579 - E585